• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
【24h】

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study

机译：关于EGFR / ALK基因状况和一线靶向治疗率的真实世界数据在新诊断的新诊断出在中国北方的新型非小细胞肺癌患者：一个潜在观察研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutation or anaplastic lymphoma kinase (ALK)-rearrangement. However, the real-world evaluation status of ALK/EGFR in China remains unclear. We conducted a prospective study including 1134 patients with cytologically or histologically confirmed advanced NSCLC (stage IIIb-IV) at 12 Chinese hospitals. The most common evaluation methods were amplification-refractory mutation system for EGFR status and immunohistochemistry targeting D5F3 for ALK status. Among patients with non-squamous, the EGFR mutation rate was 44.1% and the ALK rearrangement rate was 10.0%. Among patients with squamous cell carcinoma, the EGFR mutation rate was 8.3% and the ALK rearrangement rate was 3.7%. Among all patients, gender (HR = 1.7, 95%CI = 1.2-2.4, P = 0.006), smoking history (HR = 1.8, 95%CI = 1.3-2.7, P = 0.001), histology (HR = 5.0, 95%CI = 2.4-10.1, P 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1-2.2, P = 0.017) were independent predictors of EGFR mutation, while age (HR = 2.6, 95%CI = 1.7-4.1, P 0.001) was an independent predictor of ALK rearrangement. The median time from tumor diagnosis to EGFR or ALK status confirmation was 7 and 5 days, respectively. Targeted therapy rate was 73.8% in EGFR-positive patients and 51.4% in ALK-positive patients. There was a negative correlation between the first-line targeted therapy rate and the EGFR mutation detection period (r = -0.152, P = 0.02), while no significant correlation among patients with ALK rearrangement (r = -0.179, P = 0.076). Squamous NSCLC patients should also be routinely tested to determine their EGFR/ALK statuses. The first-line targeted therapy rate remains low in Chinese patients with NSCLC. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：酪氨酸激酶抑制剂（TKIs）可以显着延长患有先进的非小细胞肺癌（NSCLC）的患者的整体存活率，遍布表皮生长因子受体（EGFR） - utgration或Anploplastic淋巴瘤激酶（Alk） - 再定性。然而，中国ALK / EGFR的真实评价状况仍不清楚。我们进行了一项前瞻性研究，包括1134名患有细胞学或组织学诊断的晚期NSCLC（IIIB-IV）的患者，在12家中国医院。最常见的评价方法是用于EGFR状态和免疫组织化学的扩增 - 难治性突变体系，靶向D5F3的ALK状态。在非鳞状的患者中，EGFR突变率为44.1％，ALK重排速率为10.0％。在鳞状细胞癌的患者中，EGFR突变率为8.3％，ALK重排速率为3.7％。在所有患者中，性别（HR = 1.7,95％CI = 1.2-2-2.4，P = 0.006），吸烟病史（HR = 1.8,95％CI = 1.3-2.7，P = 0.001），组织学（HR = 5.0,95 ％CI = 2.4-10.1，P <0.001）和脑转移（HR = 1.5,95％CI = 1.1-2.2，P = 0.017）是EGFR突变的独立预测因子，而年龄（HR = 2.6,95％CI = 1.7-4.1，P <0.001）是ALK重排的独立预测因子。从肿瘤诊断到EGFR或ALK状态确认的中位时间分别为7和5天。 EGFR阳性患者的靶向率为73.8％，ALK阳性患者的51.4％。第一线靶向治疗率和EGFR突变检测时段之间存在负相关性（R = -0.152，P = 0.02），而ALK重排患者无显着相关性（R = -0.179，P = 0.076）。鳞状NSCLC患者也应常规测试以确定其EGFR / ALK状态。中国NSCLC患者的一线靶向治疗率较低。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号